Form 4: Dyne Therapeutics CEO Acquires Shares and Stock Options

Dyne Therapeutics CEO, John Cox, acquired 145,300 shares of common stock through restricted stock units and 232,100 stock options on December 4, 2024.

Summary

• Dyne Therapeutics CEO, John Cox, acquired 145,300 shares of common stock through restricted stock units (RSUs) on December 4, 2024.
• These RSUs will vest in equal quarterly installments over four years, starting March 4, 2025.
• Mr. Cox also acquired 232,100 stock options on the same day, with an exercise price of $29.44 per share.
• These options will vest in equal monthly installments over four years, through December 4, 2028.
• Mr. Cox also has 32,000 shares held indirectly in four trusts for the benefit of his children.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive as it aligns management with shareholder interests. The vesting schedules indicate a long-term commitment.

Positives

• The acquisition of shares and stock options by the CEO demonstrates confidence in the company's future performance.
• The vesting schedules for both the RSUs and stock options align management's interests with long-term shareholder value.

Future Outlook

The vesting schedules for the acquired shares and options suggest a long-term commitment from the CEO to the company's success.

Industry Context

This type of equity-based compensation is common for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Equity grants, including stock options and restricted stock units, are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules over four years are also typical, encouraging long-term commitment and performance.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use similar equity-based compensation structures for their executives.

Stakeholder Impact

• Shareholders may view the CEO's acquisition of shares and options as a positive sign of confidence in the company's future.
• Employees may see this as a positive sign of leadership commitment.

Key Dates

Keywords

Dyne Therapeutics, John Cox, stock options, restricted stock units, insider trading, executive compensation, equity, vesting